QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)

Jaguar Health Stock Price, News & Analysis (NASDAQ:JAGX)

$0.32
-0.07 (-17.77%)
(As of 12/5/2023 ET)
Compare
Today's Range
$0.31
$0.38
50-Day Range
$0.23
$0.46
52-Week Range
$0.21
$9.53
Volume
7.83 million shs
Average Volume
2.72 million shs
Market Capitalization
$16.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Jaguar Health MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.61mentions of Jaguar Health in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.83) to ($0.40) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.38 out of 5 stars

Medical Sector

896th out of 948 stocks

Pharmaceutical Preparations Industry

406th out of 423 stocks


JAGX stock logo

About Jaguar Health Stock (NASDAQ:JAGX)

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.

JAGX Stock Price History

JAGX Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Jaguar Health Reports Third Quarter 2023 Financial Results
Earnings Preview For Jaguar Health
See More Headlines
Receive JAGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/17/2021
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/25/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:JAGX
Fax
N/A
Employees
60
Year Founded
N/A

Profitability

Net Income
$-47,450,000.00
Net Margins
-370.40%
Pretax Margin
-380.79%

Debt

Sales & Book Value

Annual Sales
$11.96 million
Book Value
($0.32) per share

Miscellaneous

Free Float
50,675,000
Market Cap
$17.11 million
Optionable
Not Optionable
Beta
1.68
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Ms. Lisa A. Conte (Age 64)
    Founder, CEO, President & Director
    Comp: $771.4k
  • Dr. Pravin R. Chaturvedi Ph.D. (Age 60)
    Chief Scientific Officer & Chair of Scientific Advisory Board
    Comp: $539.04k
  • Mr. Jonathan S. Wolin CPA (Age 60)
    J.D., M.B.A., Chief of Staff, Chief Compliance Officer & General Counsel
    Comp: $520.29k
  • Mr. Ian H. Wendt M.B.A. (Age 55)
    Chief Commercial Officer
    Comp: $441.31k
  • Dr. Steven R. King Ph.D. (Age 65)
    Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary
    Comp: $477.66k
  • Ms. Carol R. Lizak M.B.A. (Age 59)
    Chief Financial Officer
  • Mr. Peter Hodge
    Senior Director of Investor Relations, Business Development & Special Events
  • Dr. Karen J. Brunke Ph.D. (Age 71)
    Executive VP of Corporate & Business Development
  • Mr. David Sesin
    Chief Manufacturing Officer














JAGX Stock Analysis - Frequently Asked Questions

How have JAGX shares performed in 2023?

Jaguar Health's stock was trading at $0.0869 on January 1st, 2023. Since then, JAGX shares have increased by 272.8% and is now trading at $0.3240.
View the best growth stocks for 2023 here
.

Are investors shorting Jaguar Health?

Jaguar Health saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 827,900 shares, a decrease of 26.1% from the October 31st total of 1,120,000 shares. Based on an average daily trading volume, of 4,860,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 2.3% of the company's stock are short sold.
View Jaguar Health's Short Interest
.

When is Jaguar Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024.
View our JAGX earnings forecast
.

How were Jaguar Health's earnings last quarter?

Jaguar Health, Inc. (NASDAQ:JAGX) posted its quarterly earnings results on Wednesday, November, 17th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.09. The biotechnology company earned $0.63 million during the quarter. Jaguar Health had a negative net margin of 370.40% and a negative trailing twelve-month return on equity of 1,191.67%. During the same quarter in the previous year, the company posted ($0.63) earnings per share.

When did Jaguar Health's stock split?

Jaguar Health shares reverse split on the morning of Wednesday, September 8th 2021. The 1-3 reverse split was announced on Wednesday, September 8th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 8th 2021. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

What other stocks do shareholders of Jaguar Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), Trevena (TRVN), Vaxart (VXRT), Purple Biotech (KTOV), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Biopharmx (BPMX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT).

When did Jaguar Health IPO?

(JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

Who are Jaguar Health's major shareholders?

Jaguar Health's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Jaguar Health?

Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:JAGX) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -